CorMedix (CRMD) on Tuesday reported preliminary Q1 net sales of $39 million.
Analysts polled by FactSet expected $32.3 million.
The company raised its H1 net sales guidance to a range of $62 million to $70 million from $50 million to $60 million previously, citing larger-than-expected orders in the last week of March.
Cash and short-term investments, excluding restricted cash, amounted to around $77.5 million as of March 31, CorMedix said.
CorMedix shares were more than 20% in premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。